ATC Group: N04BB01 Amantadine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N04BB01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N04 Anti-parkinson drugs
3 N04B Dopaminergic agents
4 N04BB Adamantane derivatives
5 N04BB01 Amantadine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.2 g

Active ingredients in N04BB01

Active Ingredient Description
Amantadine

Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.

Related product monographs

Title Information Source Document Type  
Symmetrel Capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Estonia (EE)

France (FR)

Hong Kong (HK)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.